Randomized Controlled Trial Comparing Embryonic Quality in rFSH Versus hMG in IVF Protocol With GnRH Antagonist
Launched by HOSPITAL DE CLINICAS DE PORTO ALEGRE · Apr 6, 2015
Trial Information
Current as of May 08, 2025
Completed
Keywords
ClinConnect Summary
To compare embryonic quality and other clinical outcomes when using human menopause gonadotropin (hMG) or recombinant follicle stimulating hormone (rFSH) to the ovarian stimulation in IVF cycles with the GnRH antagonist protocol.
Design: open randomized single center study with infertile patients submitted to IVF comparing IVF outcomes between hMG and rFSH when controlled with GnRH antagonist.
Setting: A single private center of reproductive medicine in association with Universidade Federal do Rio Grande do Sul.
Patients: Infertile women with normal ovarian reserve with IVF indication. I...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 25 to 40 y
- • infertile
- • submitted to IVF
- • no hormonal disease
- • normal FSH (\< 10)
- • anti-mullerian hormone (AMH) \> 1 ng and \< 10 ng
- • both ovaries
- • only first or second IVF
- Exclusion Criteria:
- • thyroid-stimulating hormone (TSH), prolactin (PRL) altered
- • endometrioma
- • ovarian tumor or cysts
- • previous Ovarian Hyperstimulation Syndrome (OHSS)
- • severe male factor
About Hospital De Clinicas De Porto Alegre
Hospital de Clínicas de Porto Alegre (HCPA) is a leading academic medical center in Brazil, renowned for its commitment to advancing healthcare through innovative clinical research. As a sponsor of clinical trials, HCPA leverages its extensive expertise in various medical disciplines to conduct rigorous studies aimed at improving patient outcomes and contributing to the global medical community. With a multidisciplinary team of skilled professionals and state-of-the-art facilities, HCPA fosters a collaborative environment that prioritizes ethical standards, patient safety, and scientific integrity in all its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Porto Alegre, Rgs, Brazil
Patients applied
Trial Officials
João SL Cunha Filho, Dr
Principal Investigator
Centro de Reproduçao Humana Insemine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials